What the NICE Guidelines Say About Weight Loss Injections

Step 1, Understand which NICE appraisal applies to which medicine

The first thing to get straight is that the NICE guidelines for weight loss injections are not one document. Two separate appraisals exist, covering different medicines with meaningfully different recommendations.

NICE technology appraisal TA1026, published in December 2024 and updated in September 2025, covers tirzepatide (Mounjaro). It recommends the medicine for adults with a BMI of 35 or above, alongside at least one weight-related condition from a specific list: type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the threshold is 32.5 rather than 35.

NICE technology appraisal TA875, published in March 2023, covers semaglutide (Wegovy). Its recommendations carry an additional condition: the medicine should be used for a maximum of two years, and within a specialist weight management service offering multidisciplinary support. BMI thresholds are comparable to TA1026, and the same ethnic-background adjustment applies. If you want to understand how weight loss injections sit within the wider NHS treatment landscape, the differences between these two appraisals matter from the start.

Neither appraisal is simply a green light. Both set out a review at six months: if a patient hasn't lost at least 5% of their body weight by then on the highest tolerated dose, continuing the medicine is reconsidered.

Step 2, See how NHS England is phasing real-world access

NICE recommendations create the legal basis for NHS prescribing, but NHS England controls the rollout timetable. That distinction is why a person can meet NICE criteria on paper and still be waiting. NHS England's phased approach for tirzepatide began in June 2025, when prescribing opened to adults with a BMI of 40 or above plus four or more of the five qualifying conditions. A second cohort activated in June 2026, extending access to those with a BMI of 35 to 39.9 plus four or more conditions. A further expansion towards a BMI of 40 with three conditions is planned for around March 2027.

From April 2026, GP practices have been able to prescribe tirzepatide under the updated GP contract, though participation is optional and varies between practices. You can read more about these conditions on the weight loss injections overview page. Every NHS patient who qualifies must also take part in structured diet and activity support; meeting the BMI and comorbidity criteria is necessary, but not sufficient on its own.

Wegovy on the NHS sits within specialist weight management services, where waiting lists are commonly long. That reality is what leads many people to explore the private route, where the medicine's licensed indications (broader than the NICE NHS thresholds) set the clinical floor rather than NICE eligibility.

Step 3, Know where private prescribing sits relative to the guidelines

It is worth being honest about a point that confuses a lot of people: the NICE guidelines for weight loss injection access govern NHS commissioning, not private prescribing. A private prescriber works to the medicine's licensed indication, for both tirzepatide and semaglutide, that means adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition. Those thresholds are lower than NICE's NHS ones, which is why private treatment is available to people who would not currently qualify on the NHS.

That does not mean a private consultation is a formality. Every person who approaches a weight loss treatment consultation through a regulated online pharmacy is assessed individually by a prescriber, not processed by a system. At nume, a GPhC-registered Independent Prescriber reads each consultation personally, checking medical history, current medications, and whether the treatment is genuinely suitable. You can read about how that clinical process works on our about us page.

Any pharmacy offering these medicines privately should be verifiable on the GPhC pharmacy register. That check takes about thirty seconds and is the simplest way to confirm a service is legitimate.

Step 4, What the guidelines do not change: the clinical review before every dose

One thing the NICE appraisals and the licensed indications agree on is that ongoing clinical oversight is part of the treatment, not optional extra. Both medicines are titrated gradually: tirzepatide starts at 2.5 mg and increases in four-week steps toward a maintenance dose; semaglutide follows a similar stepwise approach. A prescriber decides the pace of that titration based on how well each dose is tolerated.

Side effects are mostly gastrointestinal (nausea, changes in bowel habit, indigestion) and tend to be most noticeable at the start of a new dose, usually easing within days. The NHS patient information for tirzepatide on the NHS medicines page covers what to expect in plain language. If you experience severe, persistent stomach pain that radiates to the back, seek urgent medical advice: this is a known but infrequent warning sign for pancreatitis, highlighted by the MHRA in a January 2026 safety update.

People currently receiving treatment elsewhere can transfer to a different provider, but a prescriber will still review their history and evidence of their current dose. There is no shortcut to that step. If you'd like to understand what happens if a dose is temporarily unavailable, the information on injection shortages and restarts explains the clinical approach.

For those wondering whether these medicines are accessible in their region, guidance can differ across the four nations: the Northern Ireland weight loss injections page covers devolved access specifics. Those considering purchasing treatment should also be aware that weight loss injections are not available over the counter, a prescription following clinical assessment is a legal requirement. And if you're researching where regulated, private access is available, our guide to buying weight loss injections safely explains what to look for. Our prescribers are also available through the FAQs page for questions that don't fit neatly into a category.

If you've spent time navigating NHS referral letters and long waiting lists, the distance between knowing what NICE recommends and actually accessing treatment can feel dispiriting. That gap is real, and it is why understanding both the NHS and private routes clearly is worth the effort before you decide on next steps. Speak to our prescribers to find out whether private treatment through a GPhC-registered pharmacy is the right fit for your situation.